Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

被引：0
|
作者：
Parker, C. [1 ]
Heinrich, D. [2 ]
Helle, S., I [2 ]
O'Sullivan, J. M. [3 ]
Fossa, S. [4 ]
Chodacki, A. [5 ]
Demkow, T. [6 ]
Logue, J. [7 ]
Seke, M. [8 ]
Widmark, A. [9 ]
Johannessen, D. C. [10 ]
Nilsson, S. [11 ]
Hoskin, P. [12 ]
Bottomley, D. [13 ]
Solberg, A. [14 ]
James, N. D. [15 ]
Syndikus, I [16 ]
Wedel, S. A. [17 ]
Kliment, J. [18 ]
Cross, A.
O'Bryan-Tear, C. G. [19 ,22 ]
Garcia-Vargas, J. [20 ]
Sartor, O. [21 ]
机构：
[1] Royal Marsden Hosp, Surrey, England
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[4] Radiumhosp, Oslo, Norway
[5] Hosp Kochova, Chomutov, Czech Republic
[6] Inst Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland
[7] Christie Hosp, Manchester, Lancs, England
[8] Centrallasarettet Vaxjo, Vaxjo, Sweden
[9] Norrlands Univ Hosp, Umea, Sweden
[10] Ullevaal Univ Hosp, Oslo, Norway
[11] Karolinska Univ Sjukhuset, Stockholm, Sweden
[12] Mt Vernon Hosp, Ctr Canc, Middlesex, England
[13] St James Hosp, Leeds LS9 7TF, W Yorkshire, England
[14] St Olavs Hosp, Trondheim, Norway
[15] Inst Canc Studies, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
[16] Clatterbridge Ctr Oncol, Wirral, Merseyside, England
[17] Klinikum JW Goethe Univ, Frankfurt, Germany
[18] Martinska Fak Nemocn, Martin, Slovakia
[19] PharmaNet, Hemel Hempstead, England
[20] Bayer HealthCare Pharmaceut, Montville, NJ USA
[21] Tulane Canc Ctr, New Orleans, LA USA
[22] Algeta ASA, Oslo, Norway
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2012年 / 11卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E130 / U523
页数：2
相关论文
共 50 条
  • [1] RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES: A PHASE III RANDOMIZED TRIAL (ALSYMPCA)
    Sartor, Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas D.
    Syndikus, Isabel
    Vogelzang, Nicholas
    O'Bryan-Tear, Charles Gillies
    Garcia-Vargas, Jose
    Shan, Minghua
    Parker, Chris
    JOURNAL OF UROLOGY, 2012, 187 (04): : E279 - E279
  • [2] Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
    Parker, C.
    Heinrich, D.
    O'Sullivan, J. M.
    Fossa, S.
    Chodacki, A.
    Demkow, T.
    Cross, A.
    Bolstad, B.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 3 - 3
  • [3] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [4] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Miller, K.
    Sartor, A. O.
    Heinrich, D.
    Helle, S., I
    O'Sullivan, J. M.
    Fossa, S. D.
    Chodacki, A.
    Demkow, T.
    Logue, J. P.
    Seke, M.
    Widmark, A.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Vogelzang, N. J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2012, 35 : 238 - 239
  • [5] Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
    Vogelzang, Nicholas J.
    Parker, Chris
    Nilsson, Sten
    Coleman, Robert Edward
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] Updated Analysis of Radium-223 Dichloride (Ra-223) Impact on Survival, Safety, and Skeletal-Related Events in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases From the Phase 3 ALSYMPCA Trial
    Wedel, S.
    Kranert, T. W.
    Chodacki, A.
    Staudacher, K.
    Garcia-Vargas, J.
    Parker, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S190 - S190
  • [7] Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Wiechno, Pawel J.
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Bottomley, David
    Coleman, Robert Edward
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Parker, Chris
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Cross, Andrew
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [9] Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Kuczyk, M. A.
    Parker, C.
    Heinrich, D.
    O'Sullivan, J. M.
    Fossa, S. D.
    Chodacki, A.
    Demkow, T.
    Logue, J. P.
    Seke, M.
    Widmark, A.
    Kramer, M. W.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Cross, A.
    O'Bryan-Tear, G.
    Garcia-Vargas, J. E.
    Sartor, A. O.
    ONKOLOGIE, 2012, 35 : 182 - 182
  • [10] Results from a phase III randomized trial (ALSYMPCA) of radium-223 chloride, a first-in-class alpha-emitter, in patients with castration-resistant prostate cancer (CRPC) and bone metastases: overall survival benefit and safety profile
    O'Sullivan, J. M.
    Parker, C.
    Cross, A.
    O'Bryan-Tear, C. G.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S294 - S294
12345